Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 4/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832230 | 0.92 | KMT2A (0.39) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL831696 | 0.91 | PPARG (0.38) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL832303 | 0.90 | PPARG (0.37) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL832375 | 0.90 | KMT2A (0.42) | FLT1FLT4KDRPPARGCCR2 | |
| SCHEMBL832479 | 0.89 | KMT2A (0.38) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL831140 | 0.89 | KMT2A (0.38) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL831130 | 0.88 | KMT2A (0.39) | FLT1FLT4KDRPPARGMCL1 | |
| SCHEMBL832600 | 0.88 | ALKBH2 (0.38) | FLT1FLT4KDRPPARGCCR2 | |
| SCHEMBL862343 | 0.88 | MCL1 (0.37) | PPARGMCL1KMT2ARCE1 | |
| SCHEMBL832237 | 0.87 | KMT2A (0.38) | PPARGMCL1KMT2ARCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | FLT1 3635/4885FLT4 2781/4885KDR 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.